Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

被引：0

作者：

Harrison, Claire N. ^{[1
]}

Vannucchi, Alessandro M. ^{[2
]}

Kiladjian, Jean-Jacques ^{[3
,4
]}

Al-Ali, Haifa Kathrin ^{[5
]}

Gisslinger, Heinz ^{[6
]}

Knoops, Laurent ^{[7
,8
]}

Cervantes, Francisco ^{[9
]}

Jones, Mark M. ^{[10
]}

Sun, Kang ^{[10
]}

Descamps, Laurence ^{[11
]}

Stalbovskaya, Viktoriya ^{[12
]}

Gopalakrishna, Prashanth ^{[12
]}

Barbui, Tiziano ^{[13
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[2] Univ Florence, Florence, Italy

[3] Hop St Louis, Paris, France

[4] Univ Paris Diderot, Paris, France

[5] Univ Leipzig, D-04109 Leipzig, Germany

[6] Med Univ Vienna, Vienna, Austria

[7] Clin Univ St Luc, B-1200 Brussels, Belgium

[8] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium

[9] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

[10] Incyte Corp, Wilmington, DE USA

[11] Novartis Pharma SAS, Rueil Malmaison, France

[12] Novartis Pharma AG, Basel, Switzerland

[13] Hosp Papa Giovanni XXIII & Res Fdn, Bergamo, Italy

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)
Verstovsek, Srdan
Gupta, Vikas
Gotlib, Jason R.
Mesa, Ruben A.
Vannucchi, Alessandro M.
Kiladjian, Jean-Jacques
Cervantes, Francisco
Sun, William
Gao, Jessy
Dong, Touchuan
Naim, Ahmad
Gopalakrishna, Prashanth
Harrison, Claire N.
BLOOD, 2016, 128 (22)
[22] Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera
Verstovsek, Srdan
Passamonti, Francesco
Rambaldi, Alessandro
Barosi, Giovanni
Rosen, Peter J.
He, Shui
Contel, Nancy
Mookerjee, Bijoyesh
Rumi, Elisa
Gattoni, Elisabetta
Pieri, Lisa
Cazzola, Mario
Kantarjian, Hagop M.
Barbui, Tiziano
Vannucchi, Alessandro M.
BLOOD, 2012, 120 (21)
[23] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
Kiladjian, Jean-Jacques
Zachee, Pierre
Hino, Masayuki
Pane, Fabrizio
Masszi, Tamas
Harrison, Claire N.
Mesa, Ruben A.
Miller, Carole B.
Passamonti, Francesco
Durrant, Simon
Griesshammer, Martin
Kirito, Keita
Besses, Carles
Moiraghi, Beatriz
Rumi, Elisa
Rosti, Vittorio
Blau, Igor W.
Francillard, Nathalie
Dong, Tuochuan
Wroclawska, Monika
Vannucchi, Alessandro M.
Verstovsek, Srdan
BLOOD, 2018, 132
[24] Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
Gupta, Vikas
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason R.
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole Brennan
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie Huling
Arcasoy, Murat.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
Yacoub, Abdulraheem
Borate, Uma
Rampal, Raajit K.
Ali, Haris
Wang, Eunice
Gerds, Aaron T.
Hobbs, Gabriela S.
Kremyanskaya, Marina
Winton, Elliott
O'Connell, Casey
Goel, Swati
Oh, Stephen T.
Schiller, Gary J.
Assad, Albert
Erickson-Viitanen, Sue
Zhou, Feng
Daver, Naval
BLOOD, 2022, 140
[26] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study
Rampal, Raajit K.
Verstovsek, Srdan
Devlin, Sean M.
Stein, Eytan M.
Kadia, Tapan M.
Mauro, Michael J.
Pemmaraju, Naveen
Alvarez, Kelsey
Ard, Nicole
Goodman, Tawni
Marek, Kelly
Bose, Prithviraj
BLOOD, 2018, 132
[27] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients With Myelofibrosis: Initial Results of a Phase II Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 8 - 10
[28] 5-YEAR EFFICACY AND SAFETY OF ORAL MONTHLY IBANDRONATE: RESULTS OF THE MOBILE LONG-TERM EXTENSION STUDY
Miller, Paul D.
Recker, Robert R.
Felsenberg, Dieter
Reginster, Jean-Yves
Riis, Bente Juel
Czerwinski, Edward
Lorenc, Roman
Stakkestad, Jakob A.
Dasic, Gorana
Barr, Charles E.
Lakatos, Peter
OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S199 - S199
[29] Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
Mclnnes, Lain B.
Mease, Philip J.
Kivitz, Alan J.
Nash, Peter
Rahman, Proton
Rech, Jurgen
Conaghan, Philip G.
Kirkham, Bruce
Navarra, Sandra
Belsare, Ashwini D.
Delicha, Eumoprhia M.
Pricop, Luminita
LANCET RHEUMATOLOGY, 2020, 2 (04): : E227 - E235
[30] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason
Gupta, Vikas
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole B.
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie H., Jr.
Arcasoy, Murat O.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Jones, Mark
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 14

← 1 2 3 4 5 →